NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com ...
8d
A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be ...
Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological ...
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx management will ...
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx management will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences ...
Amylyx Pharmaceuticals, Inc. (AMLX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback